Evaluation of synbiotics as gut health improvement agents against Shiga toxin-producing isolated from the pig.

Colibacillosis is one of the major health problems in young piglets resulting in poor health and death caused by producing F18 pili and Shiga toxin 2e. It is pivotal to reduce colibacillosis in weaned piglets to enhance production performance. In this study, we evaluated synbiotics as the gut health improvement agents in the mouse model challenged with Shiga toxin-producing (STEC) isolated from piglets. Prebiotic lactulose was formulated with each 5.0 × 10 CFU/mL of GB-U15, GB-U17, and GB 1-3 to produce 3 combinations of synbiotics. A total of 40 three weeks old BALB/c mice were randomly assigned to 4 groups (n = 10): a control group and 3 synbiotics treated groups. Each treatment groups were daily administrated with 5.0 × 10 CFU/mL of one synbiotics for the first week, and every 3 days during the second week. All the mice were challenged with 8.0 × 10 CFU/mL of STEC 5 days after animals began to receive synbiotics. Mice treated with synbiotics based on GB-U15 and GB-U17 significantly improved daily weight gain compared to mice in other groups. While mice treated with GB-U15 showed better fecal index, no significant differences were observed among groups. Gross lesion and histopathological evaluations showed that mice treated with GB-U15 moderately improved recovery from STEC infection. In conclusion, our results suggest that the synbiotics formulated with lactulose and GB-U15 have potential benefits to prevent and improve colibacillosis in weaned piglets.